top of page


Bukwang initiates dosing of JM-010 in the US phase 2 study

Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that JM-010 has been administered to the first patient in phase 2 study in Europe.

In late 2019, Bukwang successfully initiated phase 2 clinical study of JM-010 in several European countries for the treatment of dyskinesia in Parkinson’s disease. The study is currently progressing as expected.

JM-010 is a new drug candidate currently being developed by Bukwang’s CNS-focus Copenhagen based subsidiary, Contera Pharma, to treat dyskinesia in Parkinson’s disease patients. Dyskinesia is a debilitating symptoms that occurs in up to 90% of patients who take levodopa long term. Currently, there is no approved treatment for this condition available in Europe thus not only investigators but also patients show strong interest in this clinical study.

Bukwang representative said, “Beginning with the first patient dosing, the company will speed up the clinical study by quickly enrolling more patients, and eventually make effective dyskinesia treatment available to Parkinson’s disease patients.”

JM-010 phase 2 clinical study in Europe is cruising, and expecting to have results in 2021.

|    ​Korean    |
bottom of page